The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Nasdaq1d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below ... patients receiving the highest dose of amycretin experienced a 22% ...
Nanexa AB: Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study
Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide. NEX-22 is a new promising treatmen ...
Mint1d
Mint Explainer: How big is the weight-loss drug market in India
It’s not just for the celebrities anymore. The ‘miracle’ weight loss drug race has arrived in India with the launch of American drugmaker Eli Lilly’s Mounjaro last week. Priced at ...
JD Supra1d
FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding
Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...
pharmaphorum4d
Novo Nordisk’s Victoza gets FDA okay for paediatric use
Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay ...